case report prostatic stromal hyperplasia with atypia · 2019. 7. 31. · course and no case of...

3
Hindawi Publishing Corporation Case Reports in Urology Volume 2013, Article ID 364124, 2 pages http://dx.doi.org/10.1155/2013/364124 Case Report Prostatic Stromal Hyperplasia with Atypia Ryan C. Hutchinson, 1 Kevin J. Wu, 2 John C. Cheville, 3 and David D. Thiel 1 1 Department of Urology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA 2 Department of Pathology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA 3 Department of Pathology, Mayo Clinic, 200 1St Street SW, Rochester, MN 55905, USA Correspondence should be addressed to David D. iel; [email protected] Received 6 February 2013; Accepted 15 May 2013 Academic Editors: A. Lophatananon and T. J. Murtola Copyright © 2013 Ryan C. Hutchinson et al. is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Prostatic stromal hyperplasia with atypia (PSHA) is a rare histologic finding diagnosed incidentally on prostate biopsies, transurethral resection specimens, and radical prostatectomy specimens. PSHA has a bizarre histologic appearance and these lesions oſten raise concern for sarcoma; however, their clinical course is indolent and does not include extraprostatic progression. We discuss a case of PHSA discovered on prostate biopsy performed for an abnormal digital rectal examination and review the literature on this rare pathologic finding. 1. Introduction Prostatic stromal hyperplasia with atypia (PSHA) is a rare histologic finding diagnosed incidentally in specimens from transrectal ultrasound (TRUS-) guided needle biopsy of the prostate, transurethral resection of prostate (TURP), radical prostatectomy, and simple prostatectomy [1]. Because of their bizarre histologic appearance, these lesions raise concern for sarcoma; however, their clinical course is indolent and does not include extraprostatic progression. 2. Case Presentation A 55-year-old man underwent a 10-core TRUS biopsy for a grossly abnormal digital rectal exam. Histologic examination (Figure 1) revealed hypercellular stroma with hyperchromatic nuclei around benign prostatic glands in 1 of the 10 cores. ere was an absence of adenocarcinoma in the remaining cores. High-power examination revealed smudgy chromatin within these cells (Figure 1 inset). e patient was reassured and placed on watchful waiting with yearly PSA examina- tions. 3. Discussion PSHA is characterized by one or more ill-defined, uncir- cumscribed, and hyperplastic stromal nodules infiltrating around benign acini [2]. Immunohistochemical staining further confirms the diagnosis by demonstrating intense immunoreactivity for androgen receptors, while being devoid of activity for estrogen receptors or Ki-67. In contrast with prostatic leiomyoma with atypia, these cells are intensely immunoreactive for vimentin instead of desmin and actin [3]. PSHA does not generally present as a symptomatic lesion in and of itself, though symptomatic cases have been reported [4]. In all cases reported, the portion of tissue comprised of PSHA was between 5–20% of the tissue, with the rest generally being typical nodular hyperplasia [1]. ese lesions, despite their atypical appearance, have a universally benign course and no case of metastatic disease has been reported, though some patients undergoing surgical management for BPH have required re-resection [5]. is finding has been referred to by a variety of names including: atypical stromal hyperplasia, symplastic leiomy- oma, and pseudoneoplastic lesion of the prostate gland. PSHA was previously grouped with low malignant potential findings such as phyllodes tumor and low-grade sarcoma as stromal tumors of unknown malignant potential (STUMP); however, given the univerally benign course of PSHA, this may constitute a misnomer. e current nomenclature emphasizes the expected indolent clinical course with treat- ment focused on the original disease of interest [3].

Upload: others

Post on 05-Mar-2021

2 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Case Report Prostatic Stromal Hyperplasia with Atypia · 2019. 7. 31. · course and no case of metastatic disease has been reported, though some patients undergoing surgical management

Hindawi Publishing CorporationCase Reports in UrologyVolume 2013, Article ID 364124, 2 pageshttp://dx.doi.org/10.1155/2013/364124

Case ReportProstatic Stromal Hyperplasia with Atypia

Ryan C. Hutchinson,1 Kevin J. Wu,2 John C. Cheville,3 and David D. Thiel1

1 Department of Urology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA2Department of Pathology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA3Department of Pathology, Mayo Clinic, 200 1St Street SW, Rochester, MN 55905, USA

Correspondence should be addressed to David D. Thiel; [email protected]

Received 6 February 2013; Accepted 15 May 2013

Academic Editors: A. Lophatananon and T. J. Murtola

Copyright © 2013 Ryan C. Hutchinson et al. This is an open access article distributed under the Creative Commons AttributionLicense, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properlycited.

Prostatic stromal hyperplasia with atypia (PSHA) is a rare histologic finding diagnosed incidentally on prostate biopsies,transurethral resection specimens, and radical prostatectomy specimens. PSHA has a bizarre histologic appearance and theselesions often raise concern for sarcoma; however, their clinical course is indolent and does not include extraprostatic progression.We discuss a case of PHSA discovered on prostate biopsy performed for an abnormal digital rectal examination and review theliterature on this rare pathologic finding.

1. Introduction

Prostatic stromal hyperplasia with atypia (PSHA) is a rarehistologic finding diagnosed incidentally in specimens fromtransrectal ultrasound (TRUS-) guided needle biopsy of theprostate, transurethral resection of prostate (TURP), radicalprostatectomy, and simple prostatectomy [1]. Because of theirbizarre histologic appearance, these lesions raise concern forsarcoma; however, their clinical course is indolent and doesnot include extraprostatic progression.

2. Case Presentation

A 55-year-old man underwent a 10-core TRUS biopsy for agrossly abnormal digital rectal exam. Histologic examination(Figure 1) revealed hypercellular stromawith hyperchromaticnuclei around benign prostatic glands in 1 of the 10 cores.There was an absence of adenocarcinoma in the remainingcores. High-power examination revealed smudgy chromatinwithin these cells (Figure 1 inset). The patient was reassuredand placed on watchful waiting with yearly PSA examina-tions.

3. Discussion

PSHA is characterized by one or more ill-defined, uncir-cumscribed, and hyperplastic stromal nodules infiltrating

around benign acini [2]. Immunohistochemical stainingfurther confirms the diagnosis by demonstrating intenseimmunoreactivity for androgen receptors, while being devoidof activity for estrogen receptors or Ki-67. In contrast withprostatic leiomyoma with atypia, these cells are intenselyimmunoreactive for vimentin instead of desmin and actin [3].

PSHA does not generally present as a symptomatic lesionin and of itself, though symptomatic cases have been reported[4]. In all cases reported, the portion of tissue comprisedof PSHA was between 5–20% of the tissue, with the restgenerally being typical nodular hyperplasia [1].These lesions,despite their atypical appearance, have a universally benigncourse and no case of metastatic disease has been reported,though some patients undergoing surgical management forBPH have required re-resection [5].

This finding has been referred to by a variety of namesincluding: atypical stromal hyperplasia, symplastic leiomy-oma, and pseudoneoplastic lesion of the prostate gland.PSHA was previously grouped with low malignant potentialfindings such as phyllodes tumor and low-grade sarcoma asstromal tumors of unknown malignant potential (STUMP);however, given the univerally benign course of PSHA,this may constitute a misnomer. The current nomenclatureemphasizes the expected indolent clinical course with treat-ment focused on the original disease of interest [3].

Page 2: Case Report Prostatic Stromal Hyperplasia with Atypia · 2019. 7. 31. · course and no case of metastatic disease has been reported, though some patients undergoing surgical management

2 Case Reports in Urology

Figure 1: H/E stain, low-power magnification (10x) with high-power inset (20x) prostatic tissue showing hypercellular stromawithatypical hyperchromatic nuclei surrounding benign prostatic glandspresent focally in one of ten needle biopsies. Inset shows a higherpower view of the atypical stromal cells with smudgy chromatin andadjacent normal prostatic acinus in lower left.

References

[1] D. Hossain, I. Meiers, J. Qian, G. T. MacLennan, and D. G.Bostwick, “Prostatic stromal hyperplasia with atypia: follow-up study of 18 cases,” Archives of Pathology and LaboratoryMedicine, vol. 132, no. 11, pp. 1729–1733, 2008.

[2] E. B. Attah andM. E. A. Powell, “Atypical stromal hyperplasia ofthe prostate gland,” American Journal of Clinical Pathology, vol.67, no. 4, pp. 324–327, 1977.

[3] M. Herawi and J. I. Epstein, “Specialized stromal tumors ofthe prostate: a clinicopathologic study of 50 cases,” AmericanJournal of Surgical Pathology, vol. 30, no. 6, pp. 694–704, 2006.

[4] J. H. Chang, A. S. Pathak, A. H. Dikranian, T. Danial, H. S. Patel,and J. A. Kaswick, “Benign prostatic stromal hyperplasia withbizarre nuclei,” Journal of Urology, vol. 170, no. 5, p. 1951, 2003.

[5] H.M.Wee, S. H.Ho, and P.H. Tan, “Recurrent prostatic stromaltumour of uncertain malignant potential (STUMP) presentingwith urinary retention 6 years after transurethral resection ofprostate (TURP),”Annals of the Academy ofMedicine Singapore,vol. 34, no. 7, pp. 441–442, 2005.

Page 3: Case Report Prostatic Stromal Hyperplasia with Atypia · 2019. 7. 31. · course and no case of metastatic disease has been reported, though some patients undergoing surgical management

Submit your manuscripts athttp://www.hindawi.com

Stem CellsInternational

Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

MEDIATORSINFLAMMATION

of

Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

Behavioural Neurology

EndocrinologyInternational Journal of

Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

Disease Markers

Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

BioMed Research International

OncologyJournal of

Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

Oxidative Medicine and Cellular Longevity

Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

PPAR Research

The Scientific World JournalHindawi Publishing Corporation http://www.hindawi.com Volume 2014

Immunology ResearchHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

Journal of

ObesityJournal of

Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

Computational and Mathematical Methods in Medicine

OphthalmologyJournal of

Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

Diabetes ResearchJournal of

Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

Research and TreatmentAIDS

Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

Gastroenterology Research and Practice

Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

Parkinson’s Disease

Evidence-Based Complementary and Alternative Medicine

Volume 2014Hindawi Publishing Corporationhttp://www.hindawi.com